SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones

-  Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe  -

See the original post here:
SELLAS Life Sciences Highlights 2020 Business and Clinical Progress and 2021 Milestones

Related Post